Last updated: September 7, 2026
Temozolomide is a mature oral oncology drug with broad generic availability, no meaningful remaining U.S. composition-of-matter exclusivity, and limited pricing power. Its market is anchored by glioblastoma and anaplastic astrocytoma treatment, where temozolomide remains part of the standard Stupp chemoradiotherapy regimen. Revenue has shifted from branded product economics to fragmented generic volume, hospital and specialty-pharmacy procurement, and demand from long-term maintenance therapy.
The commercial outlook is stable rather than high-growth. Volume is supported by continued use in newly diagnosed glioblastoma, recurrent disease, pediatric brain tumors, and selected off-label protocols. Revenue growth is constrained by generic price erosion, low innovation in the underlying molecule, and competition from newer treatment modalities rather than direct replacement by another oral alkylating agent.
What is the FDA status of temozolomide?
Temozolomide is an FDA-approved oral alkylating agent marketed originally as Temodar by Schering-Plough and later Merck. The FDA approved Temodar in 1999 for refractory anaplastic astrocytoma and expanded the label in 2005 for newly diagnosed glioblastoma in combination with radiotherapy, followed by maintenance treatment [1,2].
| Regulatory milestone |
Date |
Significance |
| Initial U.S. approval |
August 1999 |
Refractory anaplastic astrocytoma |
| Newly diagnosed glioblastoma approval |
March 2005 |
Concomitant radiotherapy and maintenance therapy |
| Active ingredient |
Temozolomide |
Oral imidazotetrazine alkylating agent |
| Main dosage forms |
Capsules; oral suspension in selected markets |
Used in oncology and neuro-oncology |
| FDA pathway |
New Drug Application |
Small-molecule approval, not biologic licensing |
| Current regulatory position |
Generic-approved product |
Multiple abbreviated new drug applications |
The principal approved U.S. indication is newly diagnosed glioblastoma, where temozolomide is administered with radiotherapy and then continued as maintenance therapy. The drug is also approved for refractory anaplastic astrocytoma. Clinical practice includes additional off-label use in recurrent glioma and other central nervous system malignancies.
What patents protected Temodar and temozolomide?
The core U.S. composition patent for temozolomide was U.S. Patent No. 5,260,291, assigned to Cancer Research Campaign Technology and related entities. The patent covered the compound and related imidazotetrazine chemistry. Its ordinary patent term expired around 2010, subject to patent-term adjustment and pediatric exclusivity considerations.
Temozolomide's commercial exclusivity was also supported by regulatory exclusivity and later formulation or use-related intellectual property. Those rights did not preserve a durable branded monopoly after generic entry.
| Patent or right |
Subject matter |
Commercial impact |
| U.S. Patent No. 5,260,291 |
Core temozolomide compound and chemistry |
Primary composition protection; expired around 2010 |
| FDA orphan-drug exclusivity |
Anaplastic astrocytoma indication |
Supported initial market protection |
| Later label and use rights |
Glioblastoma treatment regimen and approved use |
Supported commercial expansion but did not block broad generic substitution indefinitely |
| Formulation and manufacturing claims |
Process, stability, dosage-form, or impurity control |
Potentially relevant to specific products, but generally weaker than composition protection |
The practical patent position is now weak for standard temozolomide capsules. The strongest historical protection was the composition-of-matter patent. Once that right expired, manufacturers could enter with products demonstrating pharmaceutical equivalence and bioequivalence under the abbreviated new drug application pathway.
When did temozolomide lose exclusivity?
Temozolomide lost its principal U.S. composition protection around 2010. Generic versions entered the U.S. market shortly afterward, with FDA-approved products from multiple manufacturers. The timing reflected the expiration of the core patent and resolution of regulatory requirements for generic capsule products.
The 2005 glioblastoma approval created a large commercial expansion, but it did not reset the full patent term for the molecule. By the time the glioblastoma indication became the main revenue driver, temozolomide was approaching the end of its core patent life.
Temozolomide exclusivity timeline
| Period |
Market condition |
| 1999-2004 |
Branded Temodar with orphan-drug and patent protection |
| 2005-2009 |
Major growth after approval for newly diagnosed glioblastoma |
| Around 2010 |
Core composition patent expiration and generic-entry period |
| 2011-2015 |
Accelerating generic penetration and branded price pressure |
| 2016 onward |
Mature generic market with fragmented suppliers |
| 2024-2025 |
No broad U.S. branded exclusivity for standard temozolomide |
The exact commercial entry date varied by manufacturer, dosage strength, litigation posture, and regulatory approval. The relevant economic event was the loss of compound-level exclusivity, not the expiration of every formulation or process patent.
How many patents currently cover temozolomide?
No single patent count accurately describes the modern temozolomide market. Patent databases contain patents that mention temozolomide in combination therapies, pharmaceutical compositions, manufacturing processes, delivery systems, biomarkers, and treatment methods. Most do not prevent sale of a conventional generic temozolomide capsule.
For market-access analysis, patents should be divided into four groups:
- Core compound patents, which are expired.
- Product-specific formulation or process patents, which may affect a particular generic or delivery system.
- Method-of-use patents, including combination regimens and biomarker-selected treatment.
- Research-stage patents covering new combinations, nanoparticles, implants, radiosensitization, or resistance mechanisms.
The practical patent estate for conventional oral temozolomide is therefore limited. A patent search showing dozens or hundreds of documents does not establish blocking rights against standard generic capsules.
What is the Orange Book status of temozolomide?
Temozolomide has been listed in the FDA Orange Book through the Temodar reference product and associated generic products. The Orange Book identifies approved drug products, therapeutic equivalence evaluations, and patent or exclusivity information where applicable [3].
The Orange Book is most relevant for determining:
- Reference-listed drug status.
- Approved dosage forms and strengths.
- Therapeutic-equivalence codes.
- Listed patents associated with the reference product.
- Whether a generic applicant may rely on an Abbreviated New Drug Application.
For mature temozolomide capsules, the Orange Book is unlikely to provide a meaningful barrier to routine generic entry. Any remaining listed patent must be analyzed claim by claim because a patent directed to a particular use or formulation may not block all capsule products.
Which companies manufacture generic temozolomide?
Generic temozolomide has been supplied by multiple companies, including Teva Pharmaceuticals, Sandoz, Sun Pharmaceutical Industries, Accord Healthcare, Cipla, Dr. Reddy's Laboratories, and other regional manufacturers. Product availability varies by country, dose strength, procurement contract, and supply conditions.
| Manufacturer group |
Market role |
| Teva |
Large-scale generic oncology supplier |
| Sandoz |
International generic and hospital-channel supplier |
| Sun Pharma |
Broad generic oncology portfolio |
| Accord Healthcare |
Oncology-focused generic supplier |
| Cipla and Dr. Reddy's |
International and emerging-market supply |
| Merck |
Originator of Temodar; branded role materially reduced after generic entry |
Generic competition is not uniform across all strengths. Temozolomide is commonly supplied in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg capsules in the United States, although manufacturers may not offer every strength continuously.
What is the financial trajectory of temozolomide?
Temozolomide followed a classic oncology lifecycle:
- Limited initial revenue after the 1999 approval.
- Strong growth after the 2005 glioblastoma indication.
- Peak branded sales before or near generic entry.
- Rapid erosion after composition-patent expiry.
- Long-term stabilization as a lower-price generic product.
Merck's predecessor companies reported Temodar as a significant oncology product during the period when glioblastoma treatment became the primary commercial indication. Public company reporting showed annual sales in the hundreds of millions of dollars before generic erosion, but Temodar was not maintained as a separately prominent growth asset after generic competition became established [4,5].
Revenue trajectory by lifecycle stage
| Lifecycle stage |
Revenue dynamics |
Main driver |
| Pre-2005 |
Modest branded sales |
Refractory anaplastic astrocytoma |
| 2005-2009 |
Rapid expansion |
Newly diagnosed glioblastoma approval |
| 2010-2013 |
Sharp decline in branded revenue |
Generic entry and price competition |
| 2014-2019 |
Mature, fragmented market |
Stable treatment volume |
| 2020 onward |
Low-growth generic market |
Neuro-oncology prevalence and procurement economics |
Current market-research estimates for global temozolomide sales vary substantially because some reports count active pharmaceutical ingredient sales, others count branded and generic finished doses, and others include hospital procurement only. A defensible market assessment should use prescription volume and manufacturer revenue rather than relying on a single syndicated market-size estimate.
The key financial point is that temozolomide remains clinically important but is no longer a major branded-growth product. Its value is distributed among generic manufacturers, specialty distributors, oncology pharmacies, and suppliers of active pharmaceutical ingredient.
What market factors support temozolomide demand?
Demand has remained resilient for several reasons.
Glioblastoma treatment standard
Temozolomide remains embedded in the standard treatment approach for newly diagnosed glioblastoma. The Stupp regimen combines maximal safe surgery, radiotherapy, concurrent temozolomide, and maintenance temozolomide. The regimen improved survival compared with radiotherapy alone and became the benchmark for newly diagnosed disease [6].
Chronic maintenance exposure
Patients may receive multiple cycles of maintenance therapy. That creates greater unit demand than a single short-course treatment, even though the eligible patient population is relatively small.
Limited direct substitution
Few oral agents have displaced temozolomide across the full newly diagnosed glioblastoma treatment pathway. Newer approaches, including tumor-treating fields, immunotherapy trials, targeted therapy, and cellular therapies, have not eliminated routine temozolomide use.
Global oncology access
Generic temozolomide has expanded access in countries where the originator product was unaffordable. Price reductions increase treated-patient volume, particularly in markets with public oncology procurement.
What threatens temozolomide market growth?
The main threats are clinical and economic rather than patent-based.
Glioblastoma has a poor prognosis, which limits cumulative treatment duration and total addressable patient-years. Temozolomide resistance is common, especially in tumors with unfavorable molecular characteristics. The drug also causes myelosuppression, nausea, fatigue, and infection risk, which can lead to dose interruption or discontinuation.
Market pressure also comes from:
- Generic price compression.
- Hospital purchasing consolidation.
- Competing salvage regimens for recurrent disease.
- Clinical trials that replace or reduce temozolomide exposure.
- Increasing use of molecular classification, including MGMT promoter methylation status.
- Manufacturing interruptions affecting low-volume oncology strengths.
MGMT promoter methylation is associated with greater benefit from temozolomide in glioblastoma. It supports treatment selection and clinical stratification but does not create a separate commercially protected temozolomide product.
Are there formulation patents for temozolomide?
Formulation patents may cover suspension products, capsule compositions, stability profiles, particle characteristics, excipient combinations, or specific manufacturing controls. They are narrower than a compound patent and usually do not block ordinary generic capsules unless the generic product practices the protected claims.
The principal formulation opportunities are:
- Ready-to-use oral suspensions.
- Pediatric dosage forms.
- Improved stability in liquid formulations.
- Reduced handling risk for cytotoxic products.
- Modified-release or targeted delivery systems.
- Implantable or nanoparticle formulations.
- Combination products with radiosensitizers or immunomodulators.
These technologies could support differentiated pricing, but most remain niche compared with standard capsules. A commercial strategy based on a new formulation would require clinical, regulatory, and reimbursement evidence because generic capsules already satisfy the core treatment need.
What method-of-use patents cover temozolomide?
Method-of-use patents have focused on combinations, dosing schedules, patient selection, resistance modulation, radiation sequencing, and treatment of particular tumor types. Examples include claims involving glioblastoma, anaplastic astrocytoma, recurrent brain tumors, and combination treatment with other anticancer agents.
The commercial strength of a method-of-use patent depends on claim scope and prescribing behavior. A narrow regimen claim may not prevent generic sale if the product label excludes the patented use and physicians prescribe the drug for noninfringing indications. In contrast, a broad, enforceable use claim linked to the dominant indication can create greater risk, although proving induced infringement may be difficult.
Which companies are challenging Temodar patents?
The major generic challenge occurred during the transition from branded Temodar to generic temozolomide. Publicly identified generic applicants included large manufacturers such as Teva and Sandoz, among others. The commercial result was broad generic availability rather than a prolonged branded monopoly.
The original composition patent is no longer a meaningful litigation barrier. Current disputes, if any, are more likely to concern:
- Product-specific manufacturing patents.
- Formulation patents.
- ANDA patent certifications.
- Supply and quality issues.
- Hospital procurement contracts.
- Patents covering new combination therapies.
There is no current market structure comparable to an active, high-value Paragraph IV battle over a still-protected temozolomide compound.
What generic entry risks exist for temozolomide?
For a new generic entrant, the principal risks are commercial execution and supply reliability.
| Risk |
Business impact |
| Low unit prices |
Limits gross margin |
| Multiple approved suppliers |
Makes share capture difficult |
| Oncology pharmacy consolidation |
Increases contracting pressure |
| Small patient population |
Limits scale |
| Several capsule strengths |
Raises inventory complexity |
| Cytotoxic handling requirements |
Adds manufacturing and distribution controls |
| Shortages or discontinuations |
Can create temporary pricing opportunities |
| Physician familiarity with existing suppliers |
Slows switching |
Generic entry is technically feasible, but profitability depends on securing contracts, maintaining all required strengths, meeting oncology quality standards, and avoiding supply interruption.
What manufacturing and intellectual-property barriers remain?
Temozolomide is a small molecule with an established synthesis route and substantial prior-art history. The manufacturing barrier is therefore moderate rather than high. It is lower than the barrier for biologics, antibody-drug conjugates, or complex sterile injectables.
Remaining barriers include:
- Control of degradation products.
- Batch-to-batch potency consistency.
- Stability in finished capsules.
- Containment and worker safety for cytotoxic material.
- Validation of analytical methods.
- Reliable supply of active pharmaceutical ingredient.
- Regulatory documentation for multiple strengths.
- Compliance with current good manufacturing practice requirements.
The active pharmaceutical ingredient can be sourced from specialized manufacturers, but supply-chain concentration may create temporary exposure to shortages or price increases.
Does temozolomide face biosimilar competition?
No. Temozolomide is a chemically synthesized small molecule, so its relevant competitors are generic drugs, not biosimilars. Biosimilar regulation applies to biologic products under the Public Health Service Act. Temozolomide follows the small-molecule generic pathway under the Federal Food, Drug, and Cosmetic Act.
This distinction matters commercially. Generic applicants generally rely on pharmaceutical equivalence and bioequivalence rather than comparative clinical trials of the type used for biosimilar approval.
How does temozolomide compare with competing brain-cancer drugs?
| Drug or modality |
Role in glioblastoma |
Competitive position |
| Temozolomide |
Newly diagnosed disease and maintenance therapy |
Standard oral backbone; generic pricing |
| Lomustine |
Recurrent disease and selected combination regimens |
Alternative alkylating agent |
| Bevacizumab |
Recurrent glioblastoma in selected settings |
Different mechanism; not a universal substitute |
| Tumor-treating fields |
Adjunctive device-based therapy |
Adds cost and logistics rather than directly replacing temozolomide |
| Clinical-trial agents |
Investigational |
Potential long-term substitution risk |
| Carmustine wafers |
Local treatment in selected surgical settings |
Limited procedural alternative |
Temozolomide's main advantage is its established clinical role, oral administration, and relatively low generic cost. Its main weaknesses are resistance, toxicity, and limited benefit in aggressive or molecularly unfavorable disease.
What licensing deals affect temozolomide?
The major historical commercial transfer involved licensing and commercialization rights associated with the compound and Temodar. Schering-Plough commercialized temozolomide before Merck acquired Schering-Plough in 2009. Merck subsequently controlled the branded product portfolio.
No major current licensing transaction is required to commercialize conventional generic temozolomide. Licensing value is more likely to arise around:
- Novel delivery systems.
- Combination therapies.
- Biomarker-defined treatment.
- Regional distribution rights.
- Pediatric formulations.
- Oncology-supportive-care combinations.
The legacy originator rights have limited residual value for standard generic capsules.
What is the likely generic launch scenario?
A new generic entrant would likely face immediate competition in the highest-volume capsule strengths. The most realistic launch strategy would focus on supply reliability, payer and specialty-pharmacy contracts, and a complete strength portfolio.
Three scenarios are plausible:
| Scenario |
Expected outcome |
| Price-led entry |
Rapid volume acquisition but low margins |
| Reliability-led entry |
Moderate share with stronger hospital and distributor retention |
| Differentiated formulation |
Higher potential price but greater regulatory and clinical costs |
The strongest near-term commercial opportunity is not compound exclusivity. It is execution in a mature, supply-sensitive generic market.
Key Takeaways
- Temozolomide is a mature generic oncology product with no meaningful remaining U.S. composition-of-matter exclusivity.
- The original commercial product, Temodar, expanded sharply after the 2005 glioblastoma approval and then lost branded revenue after generic entry around 2010.
- Generic competition includes Teva, Sandoz, Sun Pharma, Accord, Cipla, Dr. Reddy's, and regional suppliers.
- Demand remains supported by the standard glioblastoma chemoradiotherapy and maintenance regimen.
- Biosimilar competition is irrelevant because temozolomide is a small-molecule drug.
- Remaining patent activity is concentrated in formulations, manufacturing processes, combinations, and narrow methods of use.
- Commercial upside is limited for standard capsules but may exist in liquid formulations, pediatric delivery, supply-constrained strengths, and combination products.
- The principal risks are price erosion, low market scale, clinical resistance, manufacturing quality, and procurement concentration.
FAQs
Is temozolomide still under patent in the United States?
The core U.S. compound patent expired around 2010. Later formulation or method-of-use patents may cover specific products or regimens but do not recreate broad compound exclusivity.
Can a generic manufacturer sell temozolomide for glioblastoma?
Yes. FDA-approved generic manufacturers may market temozolomide under the ANDA pathway, subject to applicable patents, labeling, bioequivalence, and regulatory requirements.
Is temozolomide a high-revenue oncology drug?
It was a significant branded oncology product before generic entry. It is now a lower-margin generic product with distributed revenue across multiple manufacturers.
Does MGMT testing create a separate market for temozolomide?
No. MGMT promoter methylation is a biomarker used to estimate treatment benefit. It does not create a separate branded temozolomide product or independent exclusivity right.
What is the strongest commercial opportunity in the temozolomide market?
The most credible opportunities are reliable supply of all capsule strengths, pediatric or liquid formulations, differentiated delivery systems, and combination products with enforceable intellectual-property protection.
References
-
U.S. Food and Drug Administration. (1999). Temodar approval letter and prescribing information. FDA.
-
U.S. Food and Drug Administration. (2005). Temodar supplemental approval for newly diagnosed glioblastoma. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Merck & Co., Inc. (2009). Annual report for the year ended December 31, 2009. Merck.
-
Schering-Plough Corporation. (2008). Annual report for the year ended December 31, 2008. Schering-Plough.
-
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., & Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987-996. https://doi.org/10.1056/NEJMoa043330
-
U.S. Patent No. 5,260,291. (1993). Imidazotetrazines and their use as antitumour agents. United States Patent and Trademark Office.
